|Mr. Joseph Truitt||Pres, CEO & Director||773.77k||N/A||1965|
|Mr. Paul Firuta||Exec. VP & COO||462.03k||N/A||1966|
|Mr. Anthony S. Gibney||Exec. VP & Chief Bus. Officer||408.66k||N/A||1971|
|Dr. Steven L. Zelenkofske||Exec. VP & Chief Medical Officer||314.81k||N/A||1959|
|Mr. Brian R. Di Donato||CFO, SVP & Treasurer||N/A||N/A||1967|
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in Blue Bell, Pennsylvania.
Achillion Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 7.